- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- August 2025
- 188 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 451 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- October 2024
- 200 Pages
Global
From €3275EUR$3,750USD£2,845GBP
- Report
- February 2025
- 218 Pages
Global
From €4191EUR$4,799USD£3,641GBP
- Report
- January 2025
- 240 Pages
Global
From €4191EUR$4,799USD£3,641GBP
- Report
- January 2025
- 153 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- February 2025
- 153 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- August 2025
- 184 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 195 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- October 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- July 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes.
Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain.
Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more